Key result
Second- and third-generation drug-eluting stents for unprotected left coronary artery trunk stenting reduced adverse cardiovascular events compared to first-generation stents.
Why the study?
To evaluate the immediate and long-term outcomes of stenting the unprotected left coronary artery trunk using different types of drug-eluting stents.
Does stenting with second- and third-generation drug-eluting stents reduce adverse cardiovascular events compared to first-generation stents in patients with stable coronary heart disease undergoing unprotected left coronary artery trunk stenting?
Cohort (n=282)
Does stenting with second- and third-generation drug-eluting stents reduce adverse cardiovascular events compared to first-generation stents in patients with stable coronary heart disease undergoing unprotected left coronary artery trunk stenting?
The use of second- and third-generation drug-eluting stents for unprotected left main coronary artery stenting significantly reduces adverse cardiovascular events and stent thrombosis compared to first-generation stents.
Answers are grounded in this paper and cite their sources.
May support newer-generation stents for unprotected left main stenting; leaves open need for randomized confirmation.
Objective. To assess the immediate and long-term results of stenting of the unprotected left coronary artery (LCA) trunk in patients, by using different types of drug-eluting stents. Material and methods. The follow-up covered 282 patients who had undergone stenting of the unprotected LCA trunk. The mean follow-up was 34.6 [33.9; 35.3] months. The patients were divided into groups according to the type of a first-, second-, and third-generation implanted stent. Results. The incidence of adverse cardiovascular events in the patients of Group 1 was significantly higher than in those in Groups 2 and 3 (29 and 7.6%, p <0.0001). The incidence of thrombosis of first-generation stents (7.0%) was significantly higher than that of second- and third-generation ones (1.6%) ( p =0.02). The incidence of adverse cardiovascular events was comparable between Groups 2 and 3, despite a shorter duration of dual antiplatelet therapy in the third-generation stent group. The absence of stent postdilatation in the LCA trunk is an independent risk factor for adverse prognosis. Conclusion. The use of second- and third-generation stents along with changes in the technical aspects of stenting of the unprotected LCA trunk leads to a substantial reduction in the risk of adverse cardiovascular events and allows the indications for intervention to be expanded in this patient category.
No takes yet. Share an insight, caveat, or question.
Arutyunyan et al. (2019) conducted a cohort in Stable coronary heart disease requiring unprotected left coronary artery trunk stenting (n=282). Second- and third-generation drug-eluting stents vs. First-generation drug-eluting stents was evaluated on Adverse cardiovascular events (p=<0.0001). Second- and third-generation drug-eluting stents for unprotected left coronary artery trunk stenting reduced adverse cardiovascular events compared to first-generation stents.
Synapse has enriched 10 related papers. Consider them for comparative context: